Antoine Adenis

Antoine Adenis

Auto-generated profile, based on publicly available information

Antoine Adenis

Service de cancérologie digestive, centre Oscar-Lambret, 59020 Lille, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2007 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
NPNicolas Penel
Nicolas Penel
SDSylvain Dewas
Sylvain Dewas
PDPhilippe Doutrelant
Philippe Doutrelant
SCStéphanie Clisant
Stéphanie Clisant
YYYazdan Yazdanpanah
Yazdan Yazdanpanah
AAAntoine Adenis
Antoine Adenis

20 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BMBohuslav Melichar
Bohuslav Melichar
AAAntoine Adenis
Antoine Adenis
LHLibor Havel
Libor Havel
ALAlbert C. Lockhart
Albert C. Lockhart
JBJaafar Bennouna
Jaafar Bennouna
EDElizabeth Claire Dees
Elizabeth Claire Dees
605 Background: MLN8237 is an investigational oral AAK inhibitor being evaluated in pts with hematologic (Ph III) and non-hematologic malignancies. We report here Ph II results from a, 5-arm study of single agent MLN8237 in pts with advanced, predominantly refractory, solid tumors (NCT01045421; closed for enrolment). Methods: Pts ≥18 years with relapsed/refractory disease measurable by RECIST, ECOG PS 0–1, and ≤2 prior (≤4 for BrC pts) cytotoxic chemotherapy regimens were enrolled. Pts with stable brain metastases were eligible. Pts were treated at the recommended Ph II dose; 50 mg BID for 7 d in 21-d cycles. For each cohort, a Simon’s 2-stage design was employed for Ph II, with ≥2 responses required in the first 20 response-evaluable pts to proceed to stage 2. The primary endpoint was overall response rate (ORR) by RECIST v1.1; safety and progression-free survival (PFS) were key secondary endpoints. Results: As of Dec 2012, 47 SCLC, 23 NSCLC, 49 BrC, 45 HNSCC and 47 GE pts in Ph II were response-evaluable (median age, 61 yrs [range 30–88]). NSCLC did not proceed to stage 2. ORR was 9%, 6%, and 4% in HNSCC, GE, and NSCLC pts, respectively; median PFS was 2.7, 1.5 and 3.1 months. BrC and SCLC data are shown in the Table. 92% of pts had a drug-related adverse event (DRAE). 57% of pts had Gr ≥3 DRAEs; including neutropenia (38%), anemia (10%), stomatitis (8%), and thrombocytopenia (6%). 22 pts died during the study; none were study-drug related. Conclusions: Single-agent activity of MLN8237 was evaluated across a range of solid tumors with a manageable toxicity profile. Encouraging Ph2 data in BrC and SCLC pts suggest that MLN8237 warrants further evaluation in these tumor types. Clinical trial information: NCT01045421.

26 September 2015 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
RRR. Ricotta
R. Ricotta
SGS. Ghezzi
S. Ghezzi
AVA. Verrioli
A. Verrioli
Luca PorcuLuca Porcu
Luca Porcu
Chiara CremoliniChiara Cremolini
Chiara Cremolini
AGA. Grothey
A. Grothey
Background: We previously described radiological changes in metastatic lesions induced byregorafenib (REGO), including cavitation of lung metastases (mets), as an imaging marker potentially associated with clinical outcome (Ricotta et al., Lancet 2013).

1 December 2017 in Annales de Pathologie
Verified
Journal Article
Closed access
FRFlorence Renaud
Florence Renaud
FBFrédéric Bibeau
Frédéric Bibeau
ELEmmanuelle Leteurtre
Emmanuelle Leteurtre
CDChristine Delaeter
Christine Delaeter
MDMalek Dib
Malek Dib
CMChristophe Mariette
Christophe Mariette